EC
AKBA icon

EntryPoint Capital’s Akebia Therapeutics AKBA Stock Holding History

EntryPoint Capital’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-201,749
Closed -$280K – 778
2026
Q1 		$280K Buy
201,749
+74,248
+58% +$102K 0.08% 496
2025
Q4 		$205K Buy
127,501
+83,050
+187% +$174K 0.08% 544
2025
Q3 		$121K Buy
44,451
+3,455
+8% +$11.5K 0.05% 610
2025
Q2 		$149K Buy
+40,996
New +$113K 0.07% 534
2024
Q2 		– Sell
-10,590
Closed -$19.4K – 1376
2024
Q1 		$19.4K Buy
+10,590
New +$16.9K 0.02% 1101

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EntryPoint Capital's AKBA Position: Q2 2026 in Review

EntryPoint Capital sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 201,749 shares — an estimated $280K sold.

EntryPoint Capital first reported a position in AKBA in Q1 2024 and held it in 5 quarters. The position peaked at $280K in Q1 2026. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • EntryPoint Capital reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • EntryPoint Capital sold 201,749 Akebia Therapeutics shares in Q2 2026, an estimated $280K.
  • EntryPoint Capital first reported a position in Akebia Therapeutics in Q1 2024 and held it in 5 quarters.
  • EntryPoint Capital's Akebia Therapeutics position peaked at $280K in Q1 2026.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.